ES2099764T3 - Formulacion a base de diltiazem. - Google Patents

Formulacion a base de diltiazem.

Info

Publication number
ES2099764T3
ES2099764T3 ES92108361T ES92108361T ES2099764T3 ES 2099764 T3 ES2099764 T3 ES 2099764T3 ES 92108361 T ES92108361 T ES 92108361T ES 92108361 T ES92108361 T ES 92108361T ES 2099764 T3 ES2099764 T3 ES 2099764T3
Authority
ES
Spain
Prior art keywords
diltiazem
formulation based
image
formulation
blend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92108361T
Other languages
English (en)
Inventor
Dennis L Hendrickson
Dan C Dimmitt
Mark S Williams
Paul F Skultety
Michael J Baltezor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of ES2099764T3 publication Critical patent/ES2099764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA A UNA FORMULA DE DILTIACEM ADECUADA PARA LA ADMINISTRACION DE UNA AL DIA. LA FORMULA CONTIENE UNA MEZCLA DE PERLAS DE DILTIACEM CON DOS PERFILES DE DISOLUCION DIFERENTES.
ES92108361T 1991-05-20 1992-05-18 Formulacion a base de diltiazem. Expired - Lifetime ES2099764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70256791A 1991-05-20 1991-05-20

Publications (1)

Publication Number Publication Date
ES2099764T3 true ES2099764T3 (es) 1997-06-01

Family

ID=24821752

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92108361T Expired - Lifetime ES2099764T3 (es) 1991-05-20 1992-05-18 Formulacion a base de diltiazem.

Country Status (17)

Country Link
EP (1) EP0514814B1 (es)
JP (1) JP3804029B2 (es)
KR (1) KR100244010B1 (es)
AT (1) ATE147982T1 (es)
AU (1) AU653223B2 (es)
CA (1) CA2068980A1 (es)
DE (1) DE69216910T2 (es)
DK (1) DK0514814T3 (es)
ES (1) ES2099764T3 (es)
FI (1) FI922270A (es)
GR (1) GR3022927T3 (es)
IE (1) IE921603A1 (es)
IL (1) IL101896A (es)
NO (1) NO921973L (es)
NZ (1) NZ242730A (es)
TW (1) TW265267B (es)
ZA (1) ZA923474B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3842815B2 (ja) * 1993-09-08 2006-11-08 ファーマシー アンド テラプティック アドバイザリー コンサルタンシー リミテッド 血管拡張剤による肝臓病および同様の症状の治療方法
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
NZ529308A (en) * 2001-04-05 2005-03-24 Collagenex Pharm Inc Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US7866376B2 (en) 2007-10-29 2011-01-11 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Heat dissipation device with U-shaped and S-shaped heat pipes
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN114425046B (zh) * 2021-12-16 2023-10-20 南通联亚药业股份有限公司 一种盐酸地尔硫卓缓释胶囊

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
JPS6215A (ja) * 1985-02-26 1987-01-06 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤
JPS62114910A (ja) * 1985-11-13 1987-05-26 エラン　コ−ポレ−シヨン　ピ−　エル　シ− 吸収がコントロ−ルされた医薬製剤
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
ES2194832T3 (es) * 1987-10-16 2003-12-01 Elan Corp Plc Formulaciones de ditiazem con absorcion controlada.
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios

Also Published As

Publication number Publication date
IE921603A1 (en) 1992-12-02
ZA923474B (en) 1993-01-27
KR920021150A (ko) 1992-12-18
ATE147982T1 (de) 1997-02-15
GR3022927T3 (en) 1997-06-30
FI922270A (fi) 1992-11-21
IL101896A (en) 1996-08-04
FI922270A0 (fi) 1992-05-19
EP0514814B1 (en) 1997-01-22
CA2068980A1 (en) 1992-11-21
AU653223B2 (en) 1994-09-22
DK0514814T3 (da) 1997-02-10
EP0514814A1 (en) 1992-11-25
DE69216910D1 (de) 1997-03-06
NO921973L (no) 1992-11-23
JP3804029B2 (ja) 2006-08-02
AU1632692A (en) 1992-11-26
KR100244010B1 (ko) 2000-03-02
DE69216910T2 (de) 1997-05-22
NO921973D0 (no) 1992-05-19
JPH05178747A (ja) 1993-07-20
NZ242730A (en) 1994-09-27
IL101896A0 (en) 1992-12-30
TW265267B (es) 1995-12-11

Similar Documents

Publication Publication Date Title
ES2099764T3 (es) Formulacion a base de diltiazem.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
DE69329992D1 (de) Farbbildprojektor
DE69415595D1 (de) Projektor
DE69215436D1 (de) Projektor
DE69209392D1 (de) Bildprojektor
DE69221807D1 (de) Farbprojektor
NO953843D0 (no) Projeksjonsbildekilde med stor lysstyrke
DE69211026D1 (de) Durchlicht-Projectionsschirm
DE69211225D1 (de) Projektor
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
FIU930584U0 (fi) Anlaeggning i samband med styrningen av en vira
DE69413112D1 (de) 5-HT3 Pyrrolopyrazinderivate
FI102522B1 (fi) Väriä kehittävä koostumus
KR940018535U (ko) 투사기의 조명계
KR940027332U (ko) 영사기용 테이블
KR940021137U (ko) 화상 투영장치의 조명계 구조
KR940026032U (ko) 영사기용 절첩식 테이블
KR930003999U (ko) 액정 프로젝터의 램프 고정장치
KR930020277U (ko) 액정 프로젝터의 풋트롤링장치
KR950009950U (ko) 브라운관 벌브 예열장치
SE9202956D0 (sv) Offset projektor
KR950012325U (ko) 투영기
KR950020487U (ko) 프로젝터
BR7100648U (pt) Queimador de vela

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514814

Country of ref document: ES